octanate (R): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410727" target="_blank" >RIV/00216208:11130/20:10410727 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/20:10410727
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=oK3HZJ5Rv4" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=oK3HZJ5Rv4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/2040620720914692" target="_blank" >10.1177/2040620720914692</a>
Alternative languages
Result language
angličtina
Original language name
octanate (R): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment
Original language description
Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate (R), a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed in 1998 in Germany, octanate (R) is approved in over 80 countries for the prevention and treatment of bleeding and for surgical prophylaxis in patients with haemophilia A, and in over 40 countries for immune tolerance induction (ITI). The manufacturing process for octanate (R) was developed to ensure high viral safety and effectively eliminates both enveloped and nonenveloped viruses. Over the past 20 years, the excellent safety and efficacy of octanate (R) have been demonstrated in pivotal clinical trials in adult and paediatric previously treated patients (PTPs) for on-demand treatment, prophylaxis and as surgical cover. Importantly, octanate (R) has displayed low immunogenicity in previously untreated patients (PUPs), with only 9.8% of PUPs developing FVIII inhibitors. octanate (R) has also shown to be highly effective in inhibitor elimination when used as ITI therapy. In a population of patients with high risk of ITI failure, success was achieved in 79.2% of patients (70.8% complete success), even when using exceptionally stringent success criteria. No relapses were observed. Here we present an overview of the clinical data with octanate (R) that support its use in a range of patient populations and clinical indications.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Therapeutic Advances in Hematology
ISSN
2040-6207
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
April
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
2040620720914692
UT code for WoS article
000529418600001
EID of the result in the Scopus database
—